-
1
-
-
84881342288
-
Curcumin: An orally bioavailable blocker of TNF and other pro-inflammatory biomarkers
-
Aggarwal BB, Gupta SC, Sung B,. 2013. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol 169: 1672 - 1692.
-
(2013)
Br J Pharmacol
, vol.169
, pp. 1672-1692
-
-
Aggarwal, B.B.1
Gupta, S.C.2
Sung, B.3
-
2
-
-
37549051274
-
Bioavailability of curcumin: Problems and promises
-
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB,. 2007. Bioavailability of curcumin: problems and promises. Mol Pharm 4: 807 - 818.
-
(2007)
Mol Pharm
, vol.4
, pp. 807-818
-
-
Anand, P.1
Kunnumakkara, A.B.2
Newman, R.A.3
Aggarwal, B.B.4
-
3
-
-
67749122326
-
Determining the effects of lipophilic drugs on membrane structure by solid-state NMR spectroscopy: The case of the antioxidant curcumin
-
Barry J, Fritz M, Brender JR, et al. 2009. Determining the effects of lipophilic drugs on membrane structure by solid-state NMR spectroscopy: the case of the antioxidant curcumin. J Am Chem Soc 131: 4490 - 4498.
-
(2009)
J Am Chem Soc
, vol.131
, pp. 4490-4498
-
-
Barry, J.1
Fritz, M.2
Brender, J.R.3
-
4
-
-
79959605403
-
Curcumin: An anti-inflammatory molecule from a curry spice on the path to cancer treatment
-
Basnet P, Skalko-Basnet N,. 2011. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 16: 4567 - 4598.
-
(2011)
Molecules
, vol.16
, pp. 4567-4598
-
-
Basnet, P.1
Skalko-Basnet, N.2
-
5
-
-
77954160638
-
Phase i dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer
-
Bayet-Robert M, Kwiatkowski F, Leheurteur M, et al. 2010. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 9: 8 - 14.
-
(2010)
Cancer Biol Ther
, vol.9
, pp. 8-14
-
-
Bayet-Robert, M.1
Kwiatkowski, F.2
Leheurteur, M.3
-
6
-
-
84895806693
-
A controlled study of a lecithinized delivery system of curcumin (Meriva®) to alleviate the adverse effects of cancer treatment
-
Belcaro G, Hosoi M, Pellegrini L, et al. 2013. A controlled study of a lecithinized delivery system of curcumin (Meriva®) to alleviate the adverse effects of cancer treatment. Phytother Res. DOI: 10.1002/ptr.5014.
-
(2013)
Phytother Res
-
-
Belcaro, G.1
Hosoi, M.2
Pellegrini, L.3
-
7
-
-
0036070626
-
Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4
-
Bhardwaj RK, Glaeser H, Becquemont L, et al. 2002. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 302: 645 - 650.
-
(2002)
J Pharmacol Exp Ther
, vol.302
, pp. 645-650
-
-
Bhardwaj, R.K.1
Glaeser, H.2
Becquemont, L.3
-
8
-
-
77449124082
-
The dark side of curcumin
-
Burgos-Moron E, Calderon-Montano JM, Salvador J, Robles A, Lopez-Lazaro M,. 2010. The dark side of curcumin. Int J Cancer 126: 1771 - 1775.
-
(2010)
Int J Cancer
, vol.126
, pp. 1771-1775
-
-
Burgos-Moron, E.1
Calderon-Montano, J.M.2
Salvador, J.3
Robles, A.4
Lopez-Lazaro, M.5
-
9
-
-
79955804832
-
Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia
-
Carroll RE, Benya RV, Turgeon DK, et al. 2011. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 4: 354 - 364.
-
(2011)
Cancer Prev Res (Phila)
, vol.4
, pp. 354-364
-
-
Carroll, R.E.1
Benya, R.V.2
Turgeon, D.K.3
-
10
-
-
0037291286
-
Safety and anti-inflammatory activity of curcumin: A component of tumeric (Curcuma longa)
-
Chainani-Wu N,. 2003. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 9: 161 - 168.
-
(2003)
J Altern Complement Med
, vol.9
, pp. 161-168
-
-
Chainani-Wu, N.1
-
11
-
-
34447563962
-
A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus
-
Chainani-Wu N, Silverman S, Jr., Reingold A, et al. 2007. A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. Phytomedicine 14: 437 - 446.
-
(2007)
Phytomedicine
, vol.14
, pp. 437-446
-
-
Chainani-Wu, N.1
Silverman, S.2
Reingold, A.3
-
12
-
-
0035174504
-
Phase i clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
-
Cheng AL, Hsu CH, Lin JK, et al. 2001. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21: 2895 - 2900.
-
(2001)
Anticancer Res
, vol.21
, pp. 2895-2900
-
-
Cheng, A.L.1
Hsu, C.H.2
Lin, J.K.3
-
13
-
-
33746353391
-
Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis
-
Cruz-Correa M, Shoskes DA, Sanchez P, et al. 2006. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4: 1035 - 1038.
-
(2006)
Clin Gastroenterol Hepatol
, vol.4
, pp. 1035-1038
-
-
Cruz-Correa, M.1
Shoskes, D.A.2
Sanchez, P.3
-
14
-
-
79955411920
-
Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation
-
Cuomo J, Appendino G, Dern AS, et al. 2011. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 74: 664 - 669.
-
(2011)
J Nat Prod
, vol.74
, pp. 664-669
-
-
Cuomo, J.1
Appendino, G.2
Dern, A.S.3
-
15
-
-
51649118928
-
Phase II trial of curcumin in patients with advanced pancreatic cancer
-
Dhillon N, Aggarwal BB, Newman RA, et al. 2008. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491 - 4499.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 4491-4499
-
-
Dhillon, N.1
Aggarwal, B.B.2
Newman, R.A.3
-
16
-
-
30744474181
-
A pilot study of the antioxidant effect of curcumin in tropical pancreatitis
-
Durgaprasad S, Pai CG, Vasanthkumar, Alvres JF, Namitha S,. 2005. A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res 122: 315 - 318.
-
(2005)
Indian J Med Res
, vol.122
, pp. 315-318
-
-
Durgaprasad, S.1
Pai, C.G.2
Vasanthkumar, A.J.3
Namitha, S.4
-
18
-
-
78249286547
-
Curcumin and gemcitabine in patients with advanced pancreatic cancer
-
Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G,. 2010. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 62: 1137 - 1141.
-
(2010)
Nutr Cancer
, vol.62
, pp. 1137-1141
-
-
Epelbaum, R.1
Schaffer, M.2
Vizel, B.3
Badmaev, V.4
Bar-Sela, G.5
-
19
-
-
12844277237
-
Consumption of the putative chemopreventive agent curcumin by cancer patients: Assessment of curcumin levels in the colorectum and their pharmacodynamic consequences
-
Garcea G, Berry DP, Jones DJ, et al. 2005. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14: 120 - 125.
-
(2005)
Cancer Epidemiol Biomarkers Prev
, vol.14
, pp. 120-125
-
-
Garcea, G.1
Berry, D.P.2
Jones, D.J.3
-
20
-
-
51349098155
-
Cytokines as a key component of cancer-related inflammation
-
Germano G, Allavena P, Mantovani A,. 2008. Cytokines as a key component of cancer-related inflammation. Cytokine 43: 374 - 379.
-
(2008)
Cytokine
, vol.43
, pp. 374-379
-
-
Germano, G.1
Allavena, P.2
Mantovani, A.3
-
21
-
-
70349466801
-
The potential role of curcumin in patients with monoclonal gammopathy of undefined significance-its effect on paraproteinemia and the urinary N-telopeptide of type i collagen bone turnover marker
-
Golombick T, Diamond TH, Badmaev V, Manoharan A, Ramakrishna R,. 2009. The potential role of curcumin in patients with monoclonal gammopathy of undefined significance-its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker. Clin Cancer Res 15: 5917 - 5922.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5917-5922
-
-
Golombick, T.1
Diamond, T.H.2
Badmaev, V.3
Manoharan, A.4
Ramakrishna, R.5
-
22
-
-
84871971567
-
Therapeutic roles of curcumin: Lessons learned from clinical trials
-
Gupta SC, Patchva S, Aggarwal BB,. 2013. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 15: 195 - 218.
-
(2013)
AAPS J
, vol.15
, pp. 195-218
-
-
Gupta, S.C.1
Patchva, S.2
Aggarwal, B.B.3
-
23
-
-
77958114117
-
Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: Antioxidant coupled with antiinflammatory
-
Hu R, Saw CL, Yu R, Kong AN,. 2010. Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory. Antioxid Redox Signal 13: 1679 - 1698.
-
(2010)
Antioxid Redox Signal
, vol.13
, pp. 1679-1698
-
-
Hu, R.1
Saw, C.L.2
Yu, R.3
Kong, A.N.4
-
24
-
-
35648983903
-
Inflammation and cancer: An ancient link with novel potentials
-
Hussain SP, Harris CC,. 2007. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121: 2373 - 2380.
-
(2007)
Int J Cancer
, vol.121
, pp. 2373-2380
-
-
Hussain, S.P.1
Harris, C.C.2
-
25
-
-
77953425009
-
Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen
-
Ide H, Tokiwa S, Sakamaki K, et al. 2010. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate 70: 1127 - 1133.
-
(2010)
Prostate
, vol.70
, pp. 1127-1133
-
-
Ide, H.1
Tokiwa, S.2
Sakamaki, K.3
-
26
-
-
0033568674
-
Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity
-
Jobin C, Bradham CA, Russo MP, et al. 1999. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 163: 3474 - 3483.
-
(1999)
J Immunol
, vol.163
, pp. 3474-3483
-
-
Jobin, C.1
Bradham, C.A.2
Russo, M.P.3
-
27
-
-
79959612772
-
A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer
-
Kanai M, Yoshimura K, Asada M, et al. 2011. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 68: 157 - 164.
-
(2011)
Cancer Chemother Pharmacol
, vol.68
, pp. 157-164
-
-
Kanai, M.1
Yoshimura, K.2
Asada, M.3
-
28
-
-
33745298519
-
Nuclear factor-kappaB in cancer development and progression
-
Karin M,. 2006. Nuclear factor-kappaB in cancer development and progression. Nature 441: 431 - 436.
-
(2006)
Nature
, vol.441
, pp. 431-436
-
-
Karin, M.1
-
29
-
-
80052832976
-
Curcumin treatment suppresses IKKbeta kinase activity of salivary cells of patients with head and neck cancer: A pilot study
-
Kim SG, Veena MS, Basak SK, et al. 2011. Curcumin treatment suppresses IKKbeta kinase activity of salivary cells of patients with head and neck cancer: a pilot study. Clin Cancer Res 17: 5953 - 5961.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5953-5961
-
-
Kim, S.G.1
Veena, M.S.2
Basak, S.K.3
-
30
-
-
79955585058
-
Cytokines, inflammation and colon cancer
-
Klampfer L,. 2011. Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets 11: 451 - 464.
-
(2011)
Curr Cancer Drug Targets
, vol.11
, pp. 451-464
-
-
Klampfer, L.1
-
31
-
-
67649407501
-
Curcumin in clinical practice: Myth or reality?
-
Mancuso C, Barone E,. 2009. Curcumin in clinical practice: myth or reality? Trends Pharmacol Sci 30: 333 - 334.
-
(2009)
Trends Pharmacol Sci
, vol.30
, pp. 333-334
-
-
Mancuso, C.1
Barone, E.2
-
32
-
-
34248385769
-
Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine
-
Marczylo TH, Verschoyle RD, Cooke DN, et al. 2007. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 60: 171 - 177.
-
(2007)
Cancer Chemother Pharmacol
, vol.60
, pp. 171-177
-
-
Marczylo, T.H.1
Verschoyle, R.D.2
Cooke, D.N.3
-
33
-
-
0035527477
-
Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer
-
McMillan DC, Elahi MM, Sattar N, et al. 2001. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 41: 64 - 69.
-
(2001)
Nutr Cancer
, vol.41
, pp. 64-69
-
-
McMillan, D.C.1
Elahi, M.M.2
Sattar, N.3
-
34
-
-
33745224326
-
A feasibility study of computer-assisted health-related quality of life data collection in patients with oral and oropharyngeal cancer
-
Millsopp L, Frackleton S, Lowe D, Rogers SN,. 2006. A feasibility study of computer-assisted health-related quality of life data collection in patients with oral and oropharyngeal cancer. Int J Oral Maxillofac Surg 35: 761 - 764.
-
(2006)
Int J Oral Maxillofac Surg
, vol.35
, pp. 761-764
-
-
Millsopp, L.1
Frackleton, S.2
Lowe, D.3
Rogers, S.N.4
-
35
-
-
84874935664
-
Effects of supplementation with curcuminoids on dyslipidemia in obese patients: A randomized crossover trial
-
Mohammadi A, Sahebkar A, Iranshahi M, et al. 2013. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res 27: 374 - 379.
-
(2013)
Phytother Res
, vol.27
, pp. 374-379
-
-
Mohammadi, A.1
Sahebkar, A.2
Iranshahi, M.3
-
36
-
-
77949875770
-
Inflammation and cancer: Causes and consequences
-
Moore MM, Chua W, Charles KA, Clarke SJ,. 2010. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther 87: 504 - 508.
-
(2010)
Clin Pharmacol Ther
, vol.87
, pp. 504-508
-
-
Moore, M.M.1
Chua, W.2
Charles, K.A.3
Clarke, S.J.4
-
37
-
-
43749098070
-
NF-kappaB and cancer-identifying targets and mechanisms
-
Naugler WE, Karin M,. 2008. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 18: 19 - 26.
-
(2008)
Curr Opin Genet Dev
, vol.18
, pp. 19-26
-
-
Naugler, W.E.1
Karin, M.2
-
38
-
-
84869485341
-
Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: Results of a randomised, double-blind, placebo-controlled trial
-
Panahi Y, Sahebkar A, Amiri M, et al. 2012a. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br J Nutr 108: 1272 - 1279.
-
(2012)
Br J Nutr
, vol.108
, pp. 1272-1279
-
-
Panahi, Y.1
Sahebkar, A.2
Amiri, M.3
-
39
-
-
84872467113
-
A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications
-
Panahi Y, Sahebkar A, Parvin S, Saadat A,. 2012b. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 49: 580 - 588.
-
(2012)
Ann Clin Biochem
, vol.49
, pp. 580-588
-
-
Panahi, Y.1
Sahebkar, A.2
Parvin, S.3
Saadat, A.4
-
40
-
-
79952496272
-
Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress
-
Rai B, Kaur J, Jacobs R, Singh J,. 2010. Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. J Oral Sci 52: 251 - 256.
-
(2010)
J Oral Sci
, vol.52
, pp. 251-256
-
-
Rai, B.1
Kaur, J.2
Jacobs, R.3
Singh, J.4
-
41
-
-
77957204556
-
Molecular mechanisms for curcumin benefits against ischemic injury
-
Sahebkar A,. 2010. Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril 94: e75 - 76; author reply e77.
-
(2010)
Fertil Steril
, vol.94
, pp. 75-76
-
-
Sahebkar, A.1
-
42
-
-
84899477785
-
Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis
-
Sahebkar A,. 2013a. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res. DOI: 10.1002/ptr.5045
-
(2013)
Phytother Res
-
-
Sahebkar, A.1
-
43
-
-
84876439194
-
Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?
-
Sahebkar A,. 2013b. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors 39: 197 - 208.
-
(2013)
Biofactors
, vol.39
, pp. 197-208
-
-
Sahebkar, A.1
-
44
-
-
84890552304
-
Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals
-
Sahebkar A, Mohammadi A, Atabati A, et al. 2013. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 27 (12): 1883 - 1888.
-
(2013)
Phytother Res
, vol.27
, Issue.12
, pp. 1883-1888
-
-
Sahebkar, A.1
Mohammadi, A.2
Atabati, A.3
-
45
-
-
77954213464
-
Supramolecular phospholipids-polyphenolics interactions: The PHYTOSOME strategy to improve the bioavailability of phytochemicals
-
Semalty A, Semalty M, Rawat MS, Franceschi F,. 2010. Supramolecular phospholipids-polyphenolics interactions: the PHYTOSOME strategy to improve the bioavailability of phytochemicals. Fitoterapia 81: 306 - 314.
-
(2010)
Fitoterapia
, vol.81
, pp. 306-314
-
-
Semalty, A.1
Semalty, M.2
Rawat, M.S.3
Franceschi, F.4
-
46
-
-
33947373996
-
Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis
-
Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A,. 2007. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: implications for the treatment of osteoarthritis. Biochem Pharmacol 73: 1434 - 1445.
-
(2007)
Biochem Pharmacol
, vol.73
, pp. 1434-1445
-
-
Shakibaei, M.1
John, T.2
Schulze-Tanzil, G.3
Lehmann, I.4
Mobasheri, A.5
-
47
-
-
6044276740
-
Phase i clinical trial of oral curcumin: Biomarkers of systemic activity and compliance
-
Sharma RA, Euden SA, Platton SL, et al. 2004. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10: 6847 - 6854.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 6847-6854
-
-
Sharma, R.A.1
Euden, S.A.2
Platton, S.L.3
-
48
-
-
0034772953
-
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer
-
Sharma RA, McLelland HR, Hill KA, et al. 2001. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7: 1894 - 1900.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 1894-1900
-
-
Sharma, R.A.1
McLelland, H.R.2
Hill, K.A.3
-
50
-
-
77956863976
-
Curcumin in cancer chemoprevention: Molecular targets, pharmacokinetics, bioavailability, and clinical trials
-
Shehzad A, Wahid F, Lee YS,. 2010. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim) 343: 489 - 499.
-
(2010)
Arch Pharm (Weinheim)
, vol.343
, pp. 489-499
-
-
Shehzad, A.1
Wahid, F.2
Lee, Y.S.3
-
51
-
-
35948951161
-
Black pepper and its pungent principle-piperine: A review of diverse physiological effects
-
Srinivasan K,. 2007. Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit Rev Food Sci Nutr 47: 735 - 748.
-
(2007)
Crit Rev Food Sci Nutr
, vol.47
, pp. 735-748
-
-
Srinivasan, K.1
-
52
-
-
38349011007
-
Curcumin: Preventive and therapeutic properties in laboratory studies and clinical trials
-
Strimpakos AS, Sharma RA,. 2008. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 10: 511 - 545.
-
(2008)
Antioxid Redox Signal
, vol.10
, pp. 511-545
-
-
Strimpakos, A.S.1
Sharma, R.A.2
-
53
-
-
46349109182
-
Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: A randomized, parallel-group, placebo-controlled, 8-week study
-
Usharani P, Mateen AA, Naidu MU, Raju YS, Chandra N,. 2008. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D 9: 243 - 250. Yamamoto Y and Gaynor RB. 2001. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 107: 135-142.
-
(2008)
Drugs R D
, vol.9
, pp. 243-250
-
-
Usharani, P.1
Mateen, A.A.2
Naidu, M.U.3
Raju, Y.S.4
Chandra, N.5
|